Zobrazeno 1 - 10
of 66
pro vyhledávání: '"Carmen, Ferrajolo"'
Autor:
Giuseppe Roberto, Anna Girardi, Francesco Barone-Adesi, Alessandro Pecere, Valentina Ientile, Claudia Bartolini, Roberto Da Cas, Stefania Spila-Alegiani, Carmen Ferrajolo, Paolo Francesconi, Gianluca Trifirò, Elisabetta Poluzzi, Fabio Baccetti, Rosa Gini
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Background: To verify whether, in patients on metformin (MET) monotherapy for type 2 diabetes (T2D), the add-on of a dipeptidyl peptidase inhibitor (DPP4i) compared to a sulfonylurea (SU) can delay the time to the subsequent treatment intensification
Externí odkaz:
https://doaj.org/article/83e9864b58da41d5af4436722a78a591
Autor:
Mario Gaio, Carmen Ferrajolo, Alessia Zinzi, Consiglia Riccardi, Pasquale Di Filippo, Ludovica Carangelo, Gorizio Pieretti, Francesco Rossi, Giovanni Francesco Nicoletti, Annalisa Capuano
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Introduction: Post-marketing data on the risks associated with direct oral anticoagulants (DOACs) are conflicting and only few studies evaluated a comparison between each different DOAC. Real-world data from pharmacovigilance databases can help to be
Externí odkaz:
https://doaj.org/article/1f0a358ed60d49e6b5c3c5cb0fa2fa7c
Autor:
Giuseppe Roberto, Francesco Barone-Adesi, Francesco Giorgianni, Valeria Pizzimenti, Carmen Ferrajolo, Michele Tari, Claudia Bartolini, Roberto Da Cas, Marina Maggini, Stefania Spila-Alegiani, Paolo Francesconi, Gianluca Trifirò, Elisabetta Poluzzi, Fabio Baccetti, Rosa Gini
Publikováno v:
BMC Endocrine Disorders, Vol 19, Iss 1, Pp 1-9 (2019)
Abstract Background The incretin-based medicines GLP1 analogues (GLP1a) and dipeptidyl peptidase-4 inhibitors (DPP4i) are hypoglycaemic agents licensed for the treatment of type 2 diabetes mellitus (T2DM). Although these drugs possess comparable effi
Externí odkaz:
https://doaj.org/article/04a605883ebf4f0e99f14d8bc520baef
Autor:
Annamaria Mascolo, Cristina Scavone, Concetta Rafaniello, Carmen Ferrajolo, Giorgio Racagni, Liberato Berrino, Giuseppe Paolisso, Francesco Rossi, Annalisa Capuano
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 7 (2020)
Although clinical manifestations of the 2019 novel coronavirus disease pandemic (COVID-19), caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-COV-2), are mainly respiratory symptoms, patients can also develop severe cardiovasc
Externí odkaz:
https://doaj.org/article/0e14bffbf95b4a83834e873cdb4df7e6
Autor:
Janet Sultana, Gianluca Trifirò, Valentina Ientile, Andrea Fontana, Francesco Rossi, Annalisa Capuano, Carmen Ferrajolo
Publikováno v:
Frontiers in Pharmacology, Vol 11 (2020)
PurposeThe aim of the present study was to describe the purchasing patterns of a set of antibiotics used exclusively in an out-patient pediatric setting in Italy using the Farma360 wholesale drug database (IQVIA Solutions Italy), identifying the prop
Externí odkaz:
https://doaj.org/article/4c53b51a377f400f9d0113df13d6562b
Autor:
Rosanna Ruggiero, Federica Fraenza, Cristina Scavone, Gabriella di Mauro, Raffaele Piscitelli, Annamaria Mascolo, Carmen Ferrajolo, Concetta Rafaniello, Liberata Sportiello, Francesco Rossi, Annalisa Capuano
Publikováno v:
Frontiers in Pharmacology, Vol 11 (2020)
BackgroundThe introduction of immune checkpoint inhibitors (ICIs) in clinical practice has brought significant benefits for patients. Seven ICIs are available in Europe: nivolumab, pembrolizumab, atezolizumab, avelumab, durvalumab, cemiplimab, and ip
Externí odkaz:
https://doaj.org/article/9c79017502904dcc95473c0b9de2f076
Autor:
Carmen Ferrajolo, Janet Sultana, Valentina Ientile, Cristina Scavone, Giulia Scondotto, Michele Tari, Gianluca Trifirò, Francesco Rossi, Annalisa Capuano
Publikováno v:
Frontiers in Pharmacology, Vol 10 (2019)
Objective: The aim of this retrospective population-based cohort study is to in-depth investigate gender-specific drug utilization pattern in pediatric outpatient population.Methods: By using a large administrative database of the Local Health Unit o
Externí odkaz:
https://doaj.org/article/cc0bc80f31e5465db8e914996bf9aa6d
Autor:
Concetta Rafaniello, Carmen Ferrajolo, Maria Giuseppa Sullo, Mario Gaio, Alessia Zinzi, Cristina Scavone, Francesca Gargano, Enrico Coscioni, Francesco Rossi, Annalisa Capuano
Publikováno v:
Pharmaceuticals, Vol 14, Iss 7, p 611 (2021)
Remdesivir was recommended for hospitalized patients with COVID-19. As already reported in the Summary of Product Characteristics, most of remdesivir’s safety concerns are hepatoxicity and nephrotoxicity related. However, some cases have raised con
Externí odkaz:
https://doaj.org/article/ce43fc69b47040c684b09c081498e0bd
Autor:
Michele Fusaroli, Valentina Isgrò, Paola Maria Cutroneo, Carmen Ferrajolo, Valentina Cirillo, Francesca Del Bufalo, Emanuel Raschi, Elisabetta Poluzzi, Gianluca Trifirò
Publikováno v:
Drug Safety. 45:891-908
As chimeric antigen receptor T-cell therapies are becoming increasingly available in the armamentarium of the hematologist, there is an emerging need to monitor post-marketing safety.We aimed to better characterize their safety profile by focusing on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba0695f751a5ffadc7c85ec0c05504c0
https://doi.org/10.1007/s40264-022-01194-z
https://doi.org/10.1007/s40264-022-01194-z
Autor:
Concetta Rafaniello, Carmen Ferrajolo, Mario Gaio, Alessia Zinzi, Cristina Scavone, Maria Giuseppa Sullo, Francesco Rossi, Liberato Berrino, Annalisa Capuano
Publikováno v:
Pharmaceuticals, Vol 13, Iss 9, p 258 (2020)
Tisagenlecleucel has revolutionized the pharmacological approach of relapsed or refractory B-cell acute lymphoblastic leukaemialeukaemia in paediatrics. The safety profile of tisagenlecleucel still needs to be better defined. The aim of this study wa
Externí odkaz:
https://doaj.org/article/1611ae4f8ecd47dcb0158848d46c1fa3